Nano medicine for pediatric rhabdomyosarcoma: drug and siRNA delivery by functionalized porous silicon nanoparticles
Nano medicine for pediatric rhabdomyosarcoma: drug and siRNA delivery by functionalized porous silicon nanoparticles
Funding:
Literature
Rengaswamy, V., Zimmer, D., Suss, R. & Rossler, J.RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.J. Control. Release 235, 319-327, (2016)
Gary‐Bobo, M., Mir, Y., Rouxel, C., Brevet, D., Basile, I., Maynadier, M., Vaillant, O., Mongin, O., Blanchard‐Desce, M., Morère, A., Garcia, M., Durand, J.‐O. and Raehm, L.Mannose‐Functionalized Mesoporous Silica Nanoparticles for Efficient Two‐Photon Photodynamic Therapy of Solid Tumors. Angew. Chem. Int. Ed., 50: 11425-11429, (2011)
Gary‐Bobo, M., Mir, Y., Rouxel, C., Brevet, D., Basile, I., Maynadier, M., Vaillant, O., Mongin, O., Blanchard‐Desce, M., Morère, A., Garcia, M., Durand, J.‐O. and Raehm, L.Mannose‐Functionalized Mesoporous Silica Nanoparticles for Efficient Two‐Photon Photodynamic Therapy of Solid Tumors. Angew. Chem. Int. Ed., 50: 11425-11429, (2011)
We aim to target and cure the very aggressive pediatric ARMS tumor with a highly specific nanomedicine approach, something that has never been achieved before.
In order to target MRD in disseminated ARMS tumor stages, we will use the recently developed multifunctional porous silicon nanoparticles (pSiNP) modified with targeting peptides to deliver chemotherapeutic agents, as well as siRNA against the PAX3-FOXO-1 fusion transcript.
In a very innovative approach, we will combine the delivery of chemotherapeutic drugs and siRNA in one NP